University of PittsburghUniversity of Pittsburgh
Startups
TechnologiesStartupsExpress LicensesCollectionsChat with AI
Sign in
University of Pittsburgh

Monarch Therapeutics, Inc.

OverviewRequest InfoMore Like ThisExpress Licenses

Sector

Therapeutics

Therapeutic Areas

ImmunologyOncology

Founders

Jason LohmuellerAlexander DeitersChristopher PottsNicholas OstroutMatthew Hewitt

Website

https://www.monarchtherapeutics.com/
Monarch Therapeutics, Inc.

Monarch Therapeutics is developing adaptable cellular immunotherapies for solid tumors. Its modular platform uses small-molecule-based adaptors to redirect engineered immune cells toward different tumor targets. The University of Pittsburgh spinout is pursuing more flexible cancer treatments, with longer-term goals that include orally available adaptors and lower manufacturing costs. [1]

Launched in December 2023, Monarch brings together scientific cofounders Jason Lohmueller and Alexander Deiters with Christopher Potts, Nicholas Ostrout and Matthew Hewitt. In May 2025, SNAP Biosciences licensed Monarch’s adaptor technology for its SNAP-CAR NK platform. [1] [2] [3]

Discover More with AI